Cytosorbents Corporation (NASDAQ:CTSO) Short Interest Update

Posted by George Bondi on Sep 24th, 2026

Cytosorbents Corporation (NASDAQ:CTSO – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 120,606 shares, a decline of 94.8% from the August 31st total of 2,306,196 shares. Approximately 4.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 45,552 shares, the days-to-cover ratio is currently 2.6 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $107.50.

Check Out Our Latest Report on Cytosorbents

Insider Buying and Selling at Cytosorbents

In related news, CEO Phillip Chan purchased 200,000 shares of the stock in a transaction dated Friday, September 4th. The stock was bought at an average cost of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the acquisition, the chief executive officer owned 1,944,432 shares of the company’s stock, valued at approximately $680,551.20. This represents a 11.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.80% of the company’s stock.

Cytosorbents Trading Down 12.4%

NASDAQ CTSO traded down $0.61 on Thursday, hitting $4.30. The company’s stock had a trading volume of 24,856 shares, compared to its average volume of 25,793. The company’s 50-day moving average is $6.87 and its 200 day moving average is $9.33. The firm has a market cap of $13.54 million, a PE ratio of -0.74 and a beta of 1.34. Cytosorbents has a 1-year low of $3.94 and a 1-year high of $20.40. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.73. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The company had revenue of $9.63 million for the quarter, compared to analyst estimates of $9.38 million. As a group, analysts predict that Cytosorbents will post -4.4 earnings per share for the current fiscal year.

Cytosorbents Company Profile

(Get Free Report)

CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components.

The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis.